Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Physiol Rep ; 11(3): e15598, 2023 02.
Artículo en Inglés | MEDLINE | ID: covidwho-2229083

RESUMEN

Hypertensive individuals taking anti-hypertensive drugs from renin-angiotensin system inhibitors may exhibit a more severe evolution of the disease when contracting the SARS-CoV-2 virus (COVID-19 disease) due to potential increases in ACE2 expression. The study investigated ACE1 and ACE2 axes and hydroxychloroquine in the lungs and adipose tissue of male and female normotensive Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHRs). SHRs were treated with losartan (10 mg/kg/day) or captopril (10 mg/kg/day) for 14 days or 7 days with hydroxychloroquine (200 mg/kg/day) in drinking water. WKY rats were also treated for 7 days with hydroxychloroquine. Blood pressure (BP), protein, and mRNA expression of ACE1 and ACE2 were analyzed in serum, adipose, and lung tissues. Losartan and captopril reduced BP in both sexes in SHR, whereas hydroxychloroquine increased BP in WKY rats. Losartan reduced ACE2 in serum and lungs in both sexes and in adipose tissue of male SHRs. Captopril decreased ACE2 protein in the lung of females and in adipose tissue in both sexes of SHRs. Hydroxychloroquine decreased ACE1 and ACE2 proteins in the lungs in both sexes and adipose tissue in male SHRs. In female WKY rats, ACE2 protein was lower only in the lungs and adipose tissue. Losartan effectively inhibited ACE2 in male and captopril in female SHRs. Hydroxychloroquine inhibited ACE2 in male SHRs and female WKY rats. These results further our understanding of the ACE2 mechanism in patients under renin-angiotensin anti-hypertensive therapy and in many trials using hydroxychloroquine for COVID-19 treatment and potential sex differences in response to drug treatment.


Asunto(s)
COVID-19 , Hipertensión , Animales , Femenino , Humanos , Masculino , Ratas , Tejido Adiposo/metabolismo , Enzima Convertidora de Angiotensina 2 , Antihipertensivos/farmacología , Presión Sanguínea , Captopril/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Hidroxicloroquina/farmacología , Hidroxicloroquina/uso terapéutico , Losartán/farmacología , Pulmón/metabolismo , Ratas Endogámicas SHR , Ratas Endogámicas WKY , SARS-CoV-2 , Peptidil-Dipeptidasa A/metabolismo
2.
Cells ; 10(6)2021 06 17.
Artículo en Inglés | MEDLINE | ID: covidwho-1369745

RESUMEN

Hypertension is associated with gut bacterial dysbiosis and gut pathology in animal models and people. Butyrate-producing gut bacteria are decreased in hypertension. RNA-seq analysis of gut colonic organoids prepared from spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto (WKY) rats was used to test the hypothesis that impaired interactions between the gut microbiome and gut epithelium are involved and that these would be remediated with butyrate supplementation. Gene expressions in immune responses including antigen presentation and antiviral pathways were decreased in the gut epithelium of the SHR in organoids and confirmed in vivo; these deficits were corrected by butyrate supplementation. Deficits in gene expression driving epithelial proliferation and differentiation were also observed in SHR. These findings highlight the importance of aligned interactions of the gut microbiome and gut immune responses to blood pressure homeostasis.


Asunto(s)
Colon/microbiología , Disbiosis , Microbioma Gastrointestinal/fisiología , Hipertensión/microbiología , Animales , Butiratos/farmacología , Colon/efectos de los fármacos , Microbioma Gastrointestinal/efectos de los fármacos , Masculino , Organoides , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY , Transcriptoma
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA